[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2021, Vol. 43 ›› Issue (7): 694-703.doi: 10.16288/j.yczz.20-423

• Technique and Method • Previous Articles     Next Articles

A method for constructing GLP-1 overexpression intestinal organoids

Zhiyang Zeng1(), Jiawei Lu1, Xiya Cao1, Xinyue Wang2,3, Dali Li1()   

  1. 1. Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, China
    2. School of Medicine, Anhui University of Science and Technology, Huainan 232000, China
    3. Department of Gastroenterology, South Campus of Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 201499, China
  • Received:2021-03-01 Revised:2021-04-14 Online:2021-07-20 Published:2021-07-20
  • Contact: Li Dali E-mail:52161300029@stu.ecnu.edu.cn;dlli@bio.ecnu.edu.cn
  • Supported by:
    Supported by the National Key R&D Program of China No(2019YFA0110802)

Abstract:

As a potent insulinotrophic hormone, glucagon-like peptide 1 (GLP-1) is mainly secreted by intestinal L cells, which can effectively promote the release of insulin and thus reduce blood glucose. Therefore, GLP-1 and its analogs have a good prospect in the treatment of type 2 diabetes. In this study, we constructed mouse intestinal organoids that overexpress GLP-1 by optimizing the GLP-1 lentivirus infection method. We found that supernatants secreted by the GLP-1 overexpression organoids effectively enhanced glucose tolerance in wild-type and diabetic mouse. Thus, the GLP-1 overexpression organoids built in this study may provide a novel strategy for the treatment of type 2 diabetes.

Key words: GLP-1, type 2 diabetes, intestinal organoids